NCT05632328 - AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 8, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2027

Conditions

Advanced Pancreatic Ductal AdenocarcinomaPancreatic Ductal AdenocarcinomaPancreatic Cancer

Interventions

DRUG

AGEN1423

via IV, dosage per protocol, once every 2 weeks for up to 8 weeks

DRUG

Botensilimab

via IV, dosage per protocol, once evert 2 weeks, up to 2 years

DRUG

Gemcitabine

per standard care

DRUG

Nab-paclitaxel

per standard care

Trial Locations (1)

Beth Israel Deaconess Medical Center, Boston